ELEMENT LISTCURRENT QUARTERSIMILAR QUARTER FOR PREVIOUS YEAR%CHANGEPREVIOUS QUARTER% CHANGE
Sales/Revenue608,544,428533,087,19314.15634,518,985-4.09
Gross Profit (Loss)225,761,071205,369,6789.93273,877,052-17.57
Operational Profit (Loss)91,400,60271,019,08528.795,306,033-4.1
Net Profit (Loss) after Zakat and Tax243,096,41254,599,836345.2374,690,225225.47
Total Comprehensive Income238,228,03348,500,974391.1874,723,664218.81
All figures are in (Actual) Saudi Arabia, Riyals
ELEMENT LISTCURRENT PERIODSIMILAR PERIOD FOR PREVIOUS YEAR%CHANGE
Sales/Revenue1,243,063,4131,127,633,05210.24
Gross Profit (Loss)499,638,123463,381,8627.82
Operational Profit (Loss)186,706,635188,226,158-0.81
Net Profit (Loss) after Zakat and Tax317,786,637105,205,604202.06
Total Comprehensive Income312,951,69786,525,793261.69
Total Share Holders Equity (after Deducting Minority Equity)1,644,592,7011,352,372,35421.61
Profit (Loss) per Share3.971.32
All figures are in (Actual) Saudi Arabia, Riyals
ELEMENT LISTEXPLANATION
The reason of the increase (decrease) in the net profit during the current quarter compared to the same quarter of the last year isNet profit increases in general due to:1. Gain from discontinued operation2. Increase in sales and gross profit in the following sectors:a) Pharmaceuticalsb) Specialty chemical
The reason of the increase (decrease) in the net profit during the current quarter compared to the previous quarter of the current year isNet profit increases in general due to:1. Gain from discontinued operation2. Decrease in selling and distribution expenses in pharmaceuticals sector.3. Decrease in general and administrative expenses in the following sectors:a) Pharmaceuticalsb) Specialty chemicalc) OtherWhile noting that there is decrease in gross profit in the following sectors:a) Pharmaceuticalsb) Specialty chemicalc) Power and steel
The reason of the increase (decrease) in the net profit during the current period compared to the same period of the last year isNet profit increases in general due to:1. Gain from discontinued operation2. Increase in sales and gross profit in the following sectors:a) Pharmaceuticalsb) Specialty chemical3. Decrease in other expenses in pharmaceuticals sector.4. Decrease in provision for impairment of financial assets in all sectors.While noting that there is increase in selling and distribution expenses and general and administrative expenses in all sectors.
Statement of the type of external auditor’s reportUnmodified conclusion
Reclassification of Comparison ItemsCertain comparative figures for the previous period have been reclassified to be consistent with the presentation of the current period.
Additional Information1. Net Shareholders’ Equity at the end of the period was SR1,644,232,915/- compared to SR1,407,057,157/- at the end of the similar period last year with an increase of 17%.2. With the completion of the sale of Al Anmaa during the period, the financial results and statements of Al Tanmiya were accounted for in accordance with IFRS requirements. Please refer to Note 13 of the condensed interim consolidated financial statements for further details.